The latest news from UKI2S and our portfolio companies
17th November 2022
Start ups may be founded by an individual with a grand vision but almost as soon as they raise the first pound a founder is joined by a nascent and fast growing team.
15th November 2022
Funding early-stage technology companies is critical for turning innovation and science into real world solutions, including those which will help us adapt to and combat climate change.
12th July 2022
We base our business model on the “power law” and estimate two out of ten early-stage investments will generate extraordinary financial return to cover the entire value of the fund.
7th June 2022
What is your most crucial piece of advice to founders and entrepreneurs building a reputation for their businesses? Make brand building a core part of your strategy…
5th May 2022
What is the most important aspect in later stage funding? Demonstrating product-market fit and associated exponential commercial growth…
26th April 2022
Steve Bennington, CEO of Q5D, speaks to UKI2S about his journey in science ventures and engineering.
21st September 2021
UKI2S is proud to invest in innovative early-stage companies, helping them to commercialise their research.
8th June 2021
Against the challenging backdrop of a global pandemic, 2020 saw the successful merger of UKI2S portfolio company Perfectus Biomed and US-based Extherid Biosciences.
24th May 2021
2021 is set to be an interesting year for gene editing. Gene therapy research is in its adolescence, and the ups and downs are played out almost every day…
22nd March 2021
Our ‘CEO Spotlight’ series seeks to recognise the wide range of diverse innovators we work with and support. In the most recent instalment, we hear from…
11th February 2021
In recognition of wide range of diverse innovators we work with and support, we are launching our ‘CEO Spotlight’ series. We will be chatting with a selection of our Portfolio Company CEO’s to learn more…
14th December 2020
Not every journey reaches its intended destination or takes the expected path en route to success. This is as true for commercialising scientific innovations as it is for any other business…
2nd November 2020
Completing a UK/US merger can be a complicated and demanding undertaking at the best of times, let alone during a global pandemic. However, for UKI2S portfolio…
27th July 2020
In our latest guest blog, Antoine Espinet, Founder and CEO of MicrofluidX, shares his insights on how to build your team, tell your story and secure investors to manage a successful fund raise.
7th July 2020
Jim Naismith is Founder and Technical Director of GyreOx, a biotechnology company recently set up with investment from the UK Innovation and Science Seed Fund (UKI2S).
18th June 2020
In the current global climate, many people – and businesses – are struggling. On both a personal and professional level, these are the start of some challenging times…
2nd June 2020
Dr Carolyn Porter, CEO of CytoSeek, shares her experiences of running a company during the coronavirus pandemic and how the Company was able to keep running as usual through these challenging times.
28th May 2020
Atelerix is a biotechnology company providing an innovative solution for storing and transporting cells and tissues at room temperature.
9th April 2020
As the COVID-19 pandemic continues, science-based companies are having to adjust their communications strategies.
10th February 2020
Barbara Domayne-Hayman is an expert in supporting early stage companies in the UK life sciences industry, both as an entrepreneur and now also on the investment side.
6th January 2020
Starting a company will always be daunting, but what specific factors should university spin-outs consider to help the process run smoothly?
20th November 2019
The success of the UK in starting and growing biotech companies is well known, but for most people the sector is synonymous only with healthcare and new medicines.
31st October 2019
Despite so much political and economic uncertainty, the UK life sciences start-up sector continues to thrive.
4th June 2013
Tim Grasby recently joined Midven as an investment manager to develop its relationship with Harwell Capital, targeting investment into UK based technology focused business.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.